TrialFuture oncology (London, England)2026

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Arun A Azad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.